Daily Bio News Summary — 2026-07-01

Today’s incremental harvest from the 9 biopharma news sites surfaced 20 candidate articles in the 30-day freshness window. After URL-dedupe against the existing news folder, only 1 article was genuinely new — the remaining 19 candidates had already been written in prior runs (mostly from the 2026-06-30 backlog and the 2026-06-29 paywall-replacement pass).

What was new today

A single fresh item:

• BeOne’s Brukinsa hits goal in lymphoma confirmatory trial (Fierce Pharma, 2026-06-30) — BeOne Medicines’ Brukinsa (zanubrutinib) met its primary endpoint in a Phase 3 confirmatory trial for relapsed/refractory mantle cell lymphoma, supporting continued regulatory momentum. This is the only news markdown file written this run.

What was deduped

19 of 20 candidates mapped onto existing sourceUrl entries in the news folder. The mix (per articles_to_write.json):

• Fierce Pharma (2): the Brukinsa trial (written today) and the Epkinly DLBCL combo win (already present from the 2026-06-30 backlog).
• BioSpace (5): FDA cell-and-gene-therapy head stepping down; Unicycive + Sobi CRL over contract manufacturing; Deerfield/Boulevard $1.6B autoimmune license from Metis TechBio; Evommune’s lead chronic-hives discontinuation; Praxis epilepsy-drug 3-month PDUFA delay; Skyhawk’s read-through from uniQure on Huntington’s pill. All six were already present from the 2026-06-30 / 2026-06-29 runs.
• STAT News (1): the Nutex Health microhospital investigation takeaways (already present from the 2026-06-30 run).
• Fierce Pharma additional (2): Viridian’s Lumvoa FDA approval vs. Amgen Tepezza; Zymeworks’ $929M Theravance buyout after Phase 3 fail (both present from the 2026-06-30 run).
• FDA Newsroom (8): PreCheck Pilot Program participant announcement; foreign tobacco-product-manufacturers rule; first single-dose generic influenza antiviral; OTC naloxone access expansion; OTC continuous glucose monitor for children; New World screwworm EUA in dogs/cats; sunscreen active-ingredient expansion (first in 20 years); draft cell-and-gene-therapy guidance (all present from the 2026-06-30 / 2026-06-29 runs).

What this batch is NOT telling us

• No fresh AI-bio items in today’s pass. Endpoints and STAT did not surface any new AI-native drug-discovery news within the 30-day window.
• No IPO or mega-round M&A — the Theravance buyout is the only M&A item and that is from the 2026-06-30 backlog.
• No top-line clinical readouts other than the BeOne Brukinsa confirmatory trial.
• No FDA AdCom calendar updates today.

The “single new article” pattern is the normal end-state of a backlog-cleanup day — when prior runs have already drained the 30-day window, the marginal write is small. The 20-candidate set is the full residual pool; the next clean harvest (likely 2026-07-02) should start producing fresh surface area again.

Reading order

For limited-time readers, the single new item to read is:

1. BeOne’s Brukinsa hits goal in lymphoma confirmatory trial (Fierce Pharma, 2026-06-30) — the new file is the only marginal news today, and the confirmatory-trial framing matters for BeOne’s standing in the BTK-inhibitor competitive set.

How to read the underlying articles

Every news file lives at ~/my-repos/openbionews.com/src/content/news/. The frontmatter carries title, description, pubDate, category, tags, sourceUrl, and sourceName. The sourceUrl field points at the original article on the publisher’s site; the sourceName field is the canonical attribution.

Today’s items, canonical citation block

1. BeOne’s Brukinsa hits goal in lymphoma confirmatory trial — Fierce Pharma, 2026-06-30.